FDA approves new drug for deadly kidney cancer

Mar 30, 2009

(AP) -- A drug from Novartis has won U.S. approval as a treatment for patients with kidney cancer that has returned after treatment with older drugs.

The approved the pill on Monday to treat renal cell cancer, the most common form of cancer.

The agency said patients tested with Novartis' Afinitor lived more than twice as long without as those who didn't receive the . The study by the Swiss drugmaker showed Afinitor delayed tumor growth nearly 5 months, compared with less than two months for patients not taking the drug.

Afinitor works by blocking a protein that helps divide and grow. The drug was approved for patients who have already taken Inc.'s Sutent and Bayer's Nexavar.

Kidney cancer is resistant to chemotherapy and radiation therapy, and the most effective remedy is usually to surgically remove the kidney. When the cancer is isolated to the kidney, a majority of patients will survive at least five years. If the cancer has spread to other parts of the body, the survival rate is much shorter.

About 13,000 patients died from the disease last year, according to the American Cancer Society.

Basel, Switzerland-based has submitted the drug for approval in the European Union, Japan and elsewhere.

Shares of Novartis fell 47 cents to close at $36.55 Monday.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: Supercomputers link proteins to drug side effects

add to favorites email to friend print save as pdf

Related Stories

FDA OKs vitamin C trial for cancer

Jan 12, 2007

Federal approval of a clinical trial on intravenous vitamin C as a cancer treatment lends credence to alternative cancer care, U.S. researchers said.

Recommended for you

Supercomputers link proteins to drug side effects

17 hours ago

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments : 0